ClinicalTrials.gg
CompletedNCT02804399Updated Jan 25, 2019Results posted

A Study To Evaluate The Effect Of Rifampin On Pharmacokinetics Of PF-06463922 In Healthy Volunteers

A Phase 1 interventional study of PF-06463922 and rifampin in Healthy, sponsored by Pfizer. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-01-25.

Sponsored by Pfizer · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to estimate the effect of rifampin on the single dose PK of PF-06463922.

Read the detailed description

This will be a Phase 1, open-label, 2-period, 2-treatment, fixed-sequence, cross-over study in approximately 12 healthy subjects employing administration of a single oral dose of PF-06463922 in the fasted state alone, and with multiple dosing of rifampin 600 mg once a day to estimate the effect of multiple dose rifampin on the single dose PK of PF-06463922.

02

Conditions studied

  • Healthy

Keywords

  • rifampin
  • pharmacokinetics
  • PF-06463922
  • drug interaction
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy female subjects of non- and/or male subjects who, at the time of screening, are between the ages of 18 and 55 years, inclusive
  • (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lbs)

Exclusion criteria

Exclusion Criteria:

  • Evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease
  • Any condition possibly affecting drug absorption
  • Positive urine drug screen
  • History of , Hep B or Hep C
  • History of regular alcohol consumption
  • History of cardiac arrhythmia, history of AV block, history of symptomatic bradycardia, history of prolongation
  • History of pancreatitis or hyperlipidemia, elevated lipase
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Other
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    all subjects

    subjects will receive a 100 mg single oral dose of PF-06463922 followed by a 100 mg single dose of PF-06463922 combined with 600 mg QD dose of rifampin with at least 10 days of washout period between two PF-06463922 doses.

    Drug: PF-06463922 · Drug: rifampin

Interventions

  • 100 mg oral dose on day 1 in period 1 and on day 8 in period 2

    Also known as: lorlatinib

  • 600 mg QD from day 1 to day 12 in period 2.

    Also known as: rifampicin

06

What researchers measure

Primary outcomes

  1. Plasma AUCinf for PF-06463922 Given Alone and With Rifampin

    AUCinf is the plasma area under the plasma concentration-time profile from time 0 extrapolated to infinite time. The pharmacokinetics (PK) parameter analysis population was defined as all participants enrolled and treated who have at least 1 of the PF-06463922 PK parameters of primary interest in at least 1 treatment period.

    Time frame: Predose, 0.5, 1, 1.5, 2, 4, 6, 12, 24, 36, 48, 60, 72, 96, 120 hours postdose on Day 1 after PF-06463922 100 mg administration in Period 1, and at the same time points on Day 8 after PF-06463922 100 mg with rifampin administration in Period 2.

  2. Plasma Cmax for PF-06463922 Given Alone and With Rifampin

    Cmax is the maximum observed plasma concentration. PK parameter analysis population was defined as all participants enrolled and treated who have at least 1 of the PF-06463922 PK parameters of primary interest in at least 1 treatment period.

    Time frame: Predose, 0.5, 1, 1.5, 2, 4, 6, 12, 24, 36, 48, 60, 72, 96, 120 hours postdose on Day 1 after PF-06463922 100 mg administration in Period 1, and at the same time points on Day 8 after PF-06463922 100 mg with rifampin administration in Period 2.

Secondary outcomes

  1. Plasma AUClast for PF-06463922 Given Alone and With Rifampin

    AUClast is the plasma area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration. The PK parameter analysis population was defined as all participants enrolled and treated who have at least 1 of the PF-06463922 PK parameters of primary interest in at least 1 treatment period.

    Time frame: Predose, 0.5, 1, 1.5, 2, 4, 6, 12, 24, 36, 48, 60, 72, 96, 120 hours postdose on Day 1 after PF-06463922 100 mg administration in Period 1, and at the same time points on Day 8 after PF-06463922 100 mg with rifampin administration in Period 2.

  2. Plasma Tmax for PF-06463922 Given Alone and With Rifampin

    Tmax is the time for maximum observed plasma concentration (Cmax). The PK parameter analysis population was defined as all participants enrolled and treated who have at least 1 of the PF-06463922 PK parameters of primary interest in at least 1 treatment period.

    Time frame: Predose, 0.5, 1, 1.5, 2, 4, 6, 12, 24, 36, 48, 60, 72, 96, 120 hours postdose on Day 1 after PF-06463922 100 mg administration in Period 1, and at the same time points on Day 8 after PF-06463922 100 mg with rifampin administration in Period 2.

  3. Plasma t1/2 for PF-06463922 Given Alone and With Rifampin

    Terminal plasma half-life (t1/2) is the time measured for the plasma concentration of drug to decrease by one half. The PK parameter analysis population is defined as all participants enrolled and treated who have at least 1 of the PF-06463922 PK parameters of primary interest in at least 1 treatment period.

    Time frame: Predose, 0.5, 1, 1.5, 2, 4, 6, 12, 24, 36, 48, 60, 72, 96, 120 hours postdose on Day 1 after PF-06463922 100 mg administration in Period 1, and at the same time points on Day 8 after PF-06463922 100 mg with rifampin administration in Period 2.

  4. Plasma CL/F for PF-06463922 Given Alone and With Rifampin

    CL/F is the apparent oral clearance. The PK parameter analysis population was defined as all participants enrolled and treated who have at least 1 of the PF-06463922 PK parameters of primary interest in at least 1 treatment period.

    Time frame: Predose, 0.5, 1, 1.5, 2, 4, 6, 12, 24, 36, 48, 60, 72, 96, 120 hours postdose on Day 1 after PF-06463922 100 mg administration in Period 1, and at the same time points on Day 8 after PF-06463922 100 mg with rifampin administration in Period 2.

  5. Plasma Vz/F for PF-06463922 Given Alone and With Rifampin

    Vz/F is the apparent volume of distribution (only after single dose).The PK parameter analysis population was defined as all participants enrolled and treated who have at least 1 of the PF-06463922 PK parameters of primary interest in at least 1 treatment period.

    Time frame: Predose, 0.5, 1, 1.5, 2, 4, 6, 12, 24, 36, 48, 60, 72, 96, 120 hours postdose on Day 1 after PF-06463922 100 mg administration in Period 1, and at the same time points on Day 8 after PF-06463922 100 mg administration with rifampin in Period 2.

  6. Plasma AUClast for PF-06895751 When PF-06463922 Given Alone and With Rifampin

    AUClast was the plasma area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration. The PK parameter analysis population was defined as all participants enrolled and treated who have at least 1 of the PF-06463922 PK parameters of primary interest in at least 1 treatment period. PF-06895751 was the metabolite of PF-06463922.

    Time frame: Predose, 0.5, 1, 1.5, 2, 4, 6, 12, 24, 36, 48, 60, 72, 96, 120 hours postdose on Day 1 after PF-06463922 100 mg administration in Period 1, and at the same time points on Day 8 after PF-06463922 100 mg with rifampin administration in Period 2.

  7. Plasma AUCinf for PF-06895751 When PF-06463922 Given Alone and With Rifampin

    AUCinf was the area under the plasma concentration-time profile from time 0 extrapolated to infinite time. The PK parameter analysis population was defined as all participants enrolled and treated who have at least 1 of the PF-06463922 PK parameters of primary interest in at least 1 treatment period. PF-06895751 was the metabolite of PF-06463922.

    Time frame: Predose, 0.5, 1, 1.5, 2, 4, 6, 12, 24, 36, 48, 60, 72, 96, 120 hours postdose on Day 1 after PF-06463922 100 mg administration in Period 1, and at the same time points on Day 8 after PF-06463922 100 mg with rifampin administration in Period 2.

  8. Plasma Tmax for PF-06895751 When PF-06463922 Given Alone and With Rifampin.

    Tmax was the time for maximum observed plasma concentration (Cmax). The PK parameter analysis population was defined as all participants enrolled and treated who have at least 1 of the PF-06463922 PK parameters of primary interest in at least 1 treatment period. PF-06895751 was the metabolite of PF-06463922.

    Time frame: Predose, 0.5, 1, 1.5, 2, 4, 6, 12, 24, 36, 48, 60, 72, 96, 120 hours postdose on Day 1 after PF-06463922 100 mg administration in Period 1, and at the same time points on Day 8 after PF-06463922 100 mg with rifampin administration in Period 2.

  9. Plasma t1/2 for PF-06895751 When PF-06463922 Given Alone and With Rifampin

    T1/2 was the terminal plasma half-life. The PK parameter analysis population was defined as all participants enrolled and treated who have at least 1 of the PF-06463922 PK parameters of primary interest in at least 1 treatment period. PF-06895751 was the metabolite of PF-06463922.

    Time frame: Predose, 0.5, 1, 1.5, 2, 4, 6, 12, 24, 36, 48, 60, 72, 96, 120 hours postdose on Day 1 after PF-06463922 100 mg administration in Period 1, and at the same time points on Day 8 after PF-06463922 100 mg with rifampin administration in Period 2.

  10. Plasma Cmax for PF-06895751 When PF-06463922 Given Alone and With Rifampin

    Cmax was the maximum observed plasma concentration. The PK parameter analysis population was defined as all participants enrolled and treated who have at least 1 of the PF-06463922 PK parameters of primary interest in at least 1 treatment period. PF-06895751 was the metabolite of PF-06463922.

    Time frame: Predose, 0.5, 1, 1.5, 2, 4, 6, 12, 24, 36, 48, 60, 72, 96, 120 hours postdose on Day 1 after PF-06463922 100 mg administration in Period 1, and at the same time points on Day 8 after PF-06463922 100 mg with rifampin administration in Period 2.

  11. Plasma Molecular Weight Adjusted Metabolite to Parent (M/P) Ratio for Cmax (MRCmax) of PF-06463922 and Its Metabolite: When PF-06463922 Given Alone and With Rifampin

    Cmax was the maximum observed plasma concentration of PF-06463922 and PF-06895751 ( metabolite of PF-06463922). The molecular weight adjusted metabolite/parent ratio (PF-06895751/PF-06463922) for Cmax was presented. The PK parameter analysis population was defined as all participants enrolled and treated who have at least 1 of the PF-06463922 PK parameters of primary interest in at least 1 treatment period.

    Time frame: Predose, 0.5, 1, 1.5, 2, 4, 6, 12, 24, 36, 48, 60, 72, 96, 120 hours postdose on Day 1 after PF-06463922 100 mg administration in Period 1, and at the same time points on Day 8 after PF-06463922 100 mg with rifampin administration in Period 2.

  12. Plasma Molecular Weight Adjusted Metabolite to Parent (M/P) Ratio for AUClast (MRAUClast) of PF-06463922 and Its Metabolite: When PF-06463922 Given Alone and With Rifampin

    AUClast was the plasma area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration of PF-06463922 and PF-06895751 ( metabolite of PF-06463922). The molecular weight adjusted metabolite/parent ratio (PF-06895751/PF-06463922) for AUClast was presented. The PK parameter analysis population was defined as all participants enrolled and treated who have at least 1 of the PF-06463922 PK parameters of primary interest in at least 1 treatment period. PF-06895751 was the metabolite of PF-06463922.

    Time frame: Predose, 0.5, 1, 1.5, 2, 4, 6, 12, 24, 36, 48, 60, 72, 96, 120 hours postdose on Day 1 after PF-06463922 100 mg administration in Period 1, and at the same time points on Day 8 after PF-06463922 100 mg with rifampin administration in Period 2.

  13. Plasma Molecular Weight Adjusted Metabolite to Parent (M/P) Ratio for AUCinf (MRAUCinf) of PF-06463922 and Its Metabolite: When PF-06463922 Given Alone and With Rifampin

    AUCinf was the plasma area under the plasma concentration-time profile from time 0 extrapolated to infinite time of PF-06463922 and PF-06895751 ( metabolite of PF-06463922). The molecular weight adjusted metabolite/parent ratio (PF-06895751/PF-06463922) for AUCinf was presented. The PK parameter analysis population was defined as all participants enrolled and treated who have at least 1 of the PF-06463922 PK parameters of primary interest in at least 1 treatment period.

    Time frame: Predose, 0.5, 1, 1.5, 2, 4, 6, 12, 24, 36, 48, 60, 72, 96, 120 hours postdose on Day 1 after PF-06463922 100 mg administration in Period 1, and at the same time points on Day 8 after PF-06463922 100 mg with rifampin administration in Period 2.

Other outcomes

  1. Number of Participants With End of Study Abnormal Laboratory Findings Meeting the Criteria of Potentially Significant Clinical Concern

    The total number of participants with laboratory test abnormalities was assessed. Clinical laboratory tests included hematology, chemistry, urinalysis and some other tests (including follicle-simulating hormone\[FSH\], urine drug screening, hepatitis B surface antigen \[HBsAg\], hepatitis B core antibody \[HBcAb\], hepatitis C virus antibody \[HCVAb\] and human immunodeficiency virus \[HIV\]. Clinical significance was judged by the investigator.

    Time frame: Baseline to about 18 days after the first PF-06463922 dose

  2. Number of Participants With Physical Examination Findings Meeting the Criteria of Potentially Significant Clinical Concern

    A full physical examination included head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, gastrointestinal, musculoskeletal, and neurological systems. The limited or abbreviated physical examination focused on general appearance, the respiratory and cardiovascular systems, as well as towards participant reported symptoms. Clinical significance was judged by the investigator.

    Time frame: Baseline to about 18 days after the first PF-06463922 dose.

  3. Number of Participants With Changes From Baseline and Absolute Values in Vital Signs Meeting the Criteria of Potentially Significant Clinical Concerns

    Criteria for potentially clinically important changes in vital signs were defined as: supine and standing systolic blood pressure (SBP) of less than (\<90) millimeters of mercury (mm Hg) or change in supine and standing SBP more than or equal to (\>=) 30 mm Hg; supine and standing diastolic blood pressure (DBP) of \< 50 mm Hg or change in supine and standing DBP of \>= 20 mm Hg; supine and standing pulse rate of \< 40 or \>120 beats per minute (bpm). Figure "99999" signifies data not measurable/applicable. Maximum Decrease is abbreviated as Max.Dec., and Maximum Increase is abbreviated as Max.Inc. n is the number of participants contributing to the parameter, not applicable is abbreviated as N/A.

    Time frame: Baseline to about 18 days after the first PF-06463922 dose.

  4. Number of Participants With Electrocardiogram (ECG) Findings Meeting the Criteria of Potentially Significant Clinical Concerns

    PR interval was the interval between the start of the P wave and the start of the QRS complex, corresponding to the time between the onset of the atrial depolarization and onset of ventricular depolarization. Criteria for potentially clinically important changes (chg) in ECG were defined as: absolute values of PR interval \>=200 to \<220 msec, \>=220 to \<240 msec, \>=240 to \<260 msec and \>=260 msec. Increase from baseline \>=40, \<60, \>=60 and \<80, \>=80, and relative change from baseline \>25%. The beginning of the Q wave to the end of the T wave corresponding to electrical systole (QT) interval corrected using the Fridericia formular (QTCF) of 450 to \<480 msec, 480 to \<500 msec and \>=500 msec, or an increase of 30 to \<60 msec of \>=60 msec. Maximum is abbreviated as Max.

    Time frame: Baseline to about 18 days after the first PF-06463922 dose.

  5. Number of Participants With Concomitant Treatments Meeting the Criteria of Potentially Significant Clinical Concerns

    Participants abstained from all concomitant treatments, except for the treatment of adverse events. Limited use of non-prescription medications that were not believed to affect participant safety or the overall results of the study might be permitted on a case by case basis following approval by the sponsor. All participants were questioned about concomitant treatment at each clinic visit. Treatments taken within 28 days before the first dose of study investigational product were documented as a prior treatment. Treatment taken after the first dose of study investigational product were documented as concomitant treatments. Females taking hormone replacement therapy might be eligible to participate in this study if they were willing to discontinue therapy at least 28 days prior to the first dose of study treatment and remained off hormonal therapy for duration of the study. Clinical significance was judged by the investigator.

    Time frame: Baseline to about 18 days after the first PF-06463922 dose.

  6. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) (All Causalities and Treatment-Related)

    An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event need not necessarily have a casual relationship with the treatment or usage. A serious adverse event (SAE) was any untoward medical occurrence at any dose that: 1) resulted in death; 2) was life threatening (immediate risk of death); 3) required inpatient hospitalization or prolongation of existing hospitalization; 4) resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); 5) resulted in congenital anomaly/birth defect. TEAE included both non-serious adverse events and serious adverse events.

    Time frame: Baseline to about 18 days after the first PF-06463922 dose.

07

Results

Posted Jan 25, 2019
Limitations and caveats
As all participants receiving co-administration of PF-06463922 (100 mg SD) with rifampin (600 mg QD) experienced drug-induced liver injury AEs, all 12 participants were discontinued from further rifampin treatment after 9 days but not 12 days.

Participant flow

Period 1
Participant flow — Period 1
MilestonePF-06463922 100 mg Single Dose (SD)Rifampin 600 Once a Day (QD) + PF-06463922 100 mg SD
Started120
Completed120
Not completed00
Washout Period at Least 10 Days
Participant flow — Washout Period at Least 10 Days
MilestonePF-06463922 100 mg Single Dose (SD)Rifampin 600 Once a Day (QD) + PF-06463922 100 mg SD
Started120
Completed120
Not completed00
Period 2
Participant flow — Period 2
MilestonePF-06463922 100 mg Single Dose (SD)Rifampin 600 Once a Day (QD) + PF-06463922 100 mg SD
Started012
Completed011
Not completed01
Withdrew: Adverse event01

Outcome measures

PrimaryPlasma AUCinf for PF-06463922 Given Alone and With Rifampin

AUCinf is the plasma area under the plasma concentration-time profile from time 0 extrapolated to infinite time. The pharmacokinetics (PK) parameter analysis population was defined as all participants enrolled and treated who have at least 1 of the PF-06463922 PK parameters of primary interest in at least 1 treatment period.

Time frame:
Predose, 0.5, 1, 1.5, 2, 4, 6, 12, 24, 36, 48, 60, 72, 96, 120 hours postdose on Day 1 after PF-06463922 100 mg administration in Period 1, and at the same time points on Day 8 after PF-06463922 100 mg with rifampin administration in Period 2.
Reported as:
Geometric mean · nanogram (ng)*hr/ millilitre (mL)
Plasma AUCinf for PF-06463922 Given Alone and With Rifampin
nanogram (ng)*hr/ millilitre (mL)PF-06463922 100 mgRifampin 600 mg + PF-06463922 100 mg
Plasma AUCinf for PF-06463922 Given Alone and With Rifampin8766 ± 191299 ± 30
Statistical analysis
  • PF-06463922 100 mg vs Rifampin 600 mg + PF-06463922 100 mg · Ratio of geometric mean: 14.74 · 90% CI 12.78 to 17.01
PrimaryPlasma Cmax for PF-06463922 Given Alone and With Rifampin

Cmax is the maximum observed plasma concentration. PK parameter analysis population was defined as all participants enrolled and treated who have at least 1 of the PF-06463922 PK parameters of primary interest in at least 1 treatment period.

Time frame:
Predose, 0.5, 1, 1.5, 2, 4, 6, 12, 24, 36, 48, 60, 72, 96, 120 hours postdose on Day 1 after PF-06463922 100 mg administration in Period 1, and at the same time points on Day 8 after PF-06463922 100 mg with rifampin administration in Period 2.
Reported as:
Geometric mean · ng/mL
Plasma Cmax for PF-06463922 Given Alone and With Rifampin
ng/mLPF-06463922 100 mgRifampin 600 mg + PF-06463922 100 mg
Plasma Cmax for PF-06463922 Given Alone and With Rifampin621.4 ± 26148.4 ± 31
Statistical analysis
  • PF-06463922 100 mg vs Rifampin 600 mg + PF-06463922 100 mg · Ratio of geometric mean: 23.88 · 90% CI 21.58 to 26.43
SecondaryPlasma AUClast for PF-06463922 Given Alone and With Rifampin

AUClast is the plasma area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration. The PK parameter analysis population was defined as all participants enrolled and treated who have at least 1 of the PF-06463922 PK parameters of primary interest in at least 1 treatment period.

Time frame:
Predose, 0.5, 1, 1.5, 2, 4, 6, 12, 24, 36, 48, 60, 72, 96, 120 hours postdose on Day 1 after PF-06463922 100 mg administration in Period 1, and at the same time points on Day 8 after PF-06463922 100 mg with rifampin administration in Period 2.
Reported as:
Geometric mean · ng•hr/mL
Plasma AUClast for PF-06463922 Given Alone and With Rifampin
ng•hr/mLPF-06463922 100 mgRifampin 600 mg + PF-06463922 100 mg
Plasma AUClast for PF-06463922 Given Alone and With Rifampin8597 ± 191200 ± 32
Statistical analysis
  • PF-06463922 100 mg vs Rifampin 600 mg + PF-06463922 100 mg · Ratio of geometric mean: 13.96 · 90% CI 12.09 to 16.12
SecondaryPlasma Tmax for PF-06463922 Given Alone and With Rifampin

Tmax is the time for maximum observed plasma concentration (Cmax). The PK parameter analysis population was defined as all participants enrolled and treated who have at least 1 of the PF-06463922 PK parameters of primary interest in at least 1 treatment period.

Time frame:
Predose, 0.5, 1, 1.5, 2, 4, 6, 12, 24, 36, 48, 60, 72, 96, 120 hours postdose on Day 1 after PF-06463922 100 mg administration in Period 1, and at the same time points on Day 8 after PF-06463922 100 mg with rifampin administration in Period 2.
Reported as:
Median · hr
Plasma Tmax for PF-06463922 Given Alone and With Rifampin
hrPF-06463922 100 mgRifampin 600 mg + PF-06463922 100 mg
Plasma Tmax for PF-06463922 Given Alone and With Rifampin1.50 (0.683 to 2.00)1.51 (1.00 to 4.00)
SecondaryPlasma t1/2 for PF-06463922 Given Alone and With Rifampin

Terminal plasma half-life (t1/2) is the time measured for the plasma concentration of drug to decrease by one half. The PK parameter analysis population is defined as all participants enrolled and treated who have at least 1 of the PF-06463922 PK parameters of primary interest in at least 1 treatment period.

Time frame:
Predose, 0.5, 1, 1.5, 2, 4, 6, 12, 24, 36, 48, 60, 72, 96, 120 hours postdose on Day 1 after PF-06463922 100 mg administration in Period 1, and at the same time points on Day 8 after PF-06463922 100 mg with rifampin administration in Period 2.
Reported as:
Mean · hr
Plasma t1/2 for PF-06463922 Given Alone and With Rifampin
hrPF-06463922 100 mgRifampin 600 mg + PF-06463922 100 mg
Plasma t1/2 for PF-06463922 Given Alone and With Rifampin21.22 ± 4.1210.16 ± 2.43
SecondaryPlasma CL/F for PF-06463922 Given Alone and With Rifampin

CL/F is the apparent oral clearance. The PK parameter analysis population was defined as all participants enrolled and treated who have at least 1 of the PF-06463922 PK parameters of primary interest in at least 1 treatment period.

Time frame:
Predose, 0.5, 1, 1.5, 2, 4, 6, 12, 24, 36, 48, 60, 72, 96, 120 hours postdose on Day 1 after PF-06463922 100 mg administration in Period 1, and at the same time points on Day 8 after PF-06463922 100 mg with rifampin administration in Period 2.
Reported as:
Geometric mean · L/hr
Plasma CL/F for PF-06463922 Given Alone and With Rifampin
L/hrPF-06463922 100 mgRifampin 600 mg + PF-06463922 100 mg
Plasma CL/F for PF-06463922 Given Alone and With Rifampin11.39 ± 2076.91 ± 30
SecondaryPlasma Vz/F for PF-06463922 Given Alone and With Rifampin

Vz/F is the apparent volume of distribution (only after single dose).The PK parameter analysis population was defined as all participants enrolled and treated who have at least 1 of the PF-06463922 PK parameters of primary interest in at least 1 treatment period.

Time frame:
Predose, 0.5, 1, 1.5, 2, 4, 6, 12, 24, 36, 48, 60, 72, 96, 120 hours postdose on Day 1 after PF-06463922 100 mg administration in Period 1, and at the same time points on Day 8 after PF-06463922 100 mg administration with rifampin in Period 2.
Reported as:
Geometric mean · liter
Plasma Vz/F for PF-06463922 Given Alone and With Rifampin
literPF-06463922 100 mgRifampin 600 mg + PF-06463922 100 mg
Plasma Vz/F for PF-06463922 Given Alone and With Rifampin342.6 ± 191095 ± 47
SecondaryPlasma AUClast for PF-06895751 When PF-06463922 Given Alone and With Rifampin

AUClast was the plasma area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration. The PK parameter analysis population was defined as all participants enrolled and treated who have at least 1 of the PF-06463922 PK parameters of primary interest in at least 1 treatment period. PF-06895751 was the metabolite of PF-06463922.

Time frame:
Predose, 0.5, 1, 1.5, 2, 4, 6, 12, 24, 36, 48, 60, 72, 96, 120 hours postdose on Day 1 after PF-06463922 100 mg administration in Period 1, and at the same time points on Day 8 after PF-06463922 100 mg with rifampin administration in Period 2.
Reported as:
Geometric mean · ng*hr/mL
Plasma AUClast for PF-06895751 When PF-06463922 Given Alone and With Rifampin
ng*hr/mLPF-06463922 100 mgRifampin 600 mg + PF-06463922 100 mg
Plasma AUClast for PF-06895751 When PF-06463922 Given Alone and With Rifampin4105 ± 333169 ± 60
SecondaryPlasma AUCinf for PF-06895751 When PF-06463922 Given Alone and With Rifampin

AUCinf was the area under the plasma concentration-time profile from time 0 extrapolated to infinite time. The PK parameter analysis population was defined as all participants enrolled and treated who have at least 1 of the PF-06463922 PK parameters of primary interest in at least 1 treatment period. PF-06895751 was the metabolite of PF-06463922.

Time frame:
Predose, 0.5, 1, 1.5, 2, 4, 6, 12, 24, 36, 48, 60, 72, 96, 120 hours postdose on Day 1 after PF-06463922 100 mg administration in Period 1, and at the same time points on Day 8 after PF-06463922 100 mg with rifampin administration in Period 2.
Reported as:
Geometric mean · ng•hr/mL
Plasma AUCinf for PF-06895751 When PF-06463922 Given Alone and With Rifampin
ng•hr/mLPF-06463922 100 mgRifampin 600 mg + PF-06463922 100 mg
Plasma AUCinf for PF-06895751 When PF-06463922 Given Alone and With Rifampin4453 ± 383291 ± 60
SecondaryPlasma Tmax for PF-06895751 When PF-06463922 Given Alone and With Rifampin.

Tmax was the time for maximum observed plasma concentration (Cmax). The PK parameter analysis population was defined as all participants enrolled and treated who have at least 1 of the PF-06463922 PK parameters of primary interest in at least 1 treatment period. PF-06895751 was the metabolite of PF-06463922.

Time frame:
Predose, 0.5, 1, 1.5, 2, 4, 6, 12, 24, 36, 48, 60, 72, 96, 120 hours postdose on Day 1 after PF-06463922 100 mg administration in Period 1, and at the same time points on Day 8 after PF-06463922 100 mg with rifampin administration in Period 2.
Reported as:
Median · hr
Plasma Tmax for PF-06895751 When PF-06463922 Given Alone and With Rifampin.
hrPF-06463922 100 mgRifampin 600 mg + PF-06463922 100 mg
Plasma Tmax for PF-06895751 When PF-06463922 Given Alone and With Rifampin.30.1 (24.0 to 36.1)12.0 (6.00 to 36.1)
SecondaryPlasma t1/2 for PF-06895751 When PF-06463922 Given Alone and With Rifampin

T1/2 was the terminal plasma half-life. The PK parameter analysis population was defined as all participants enrolled and treated who have at least 1 of the PF-06463922 PK parameters of primary interest in at least 1 treatment period. PF-06895751 was the metabolite of PF-06463922.

Time frame:
Predose, 0.5, 1, 1.5, 2, 4, 6, 12, 24, 36, 48, 60, 72, 96, 120 hours postdose on Day 1 after PF-06463922 100 mg administration in Period 1, and at the same time points on Day 8 after PF-06463922 100 mg with rifampin administration in Period 2.
Reported as:
Mean · hr
Plasma t1/2 for PF-06895751 When PF-06463922 Given Alone and With Rifampin
hrPF-06463922 100 mgRifampin 600 mg + PF-06463922 100 mg
Plasma t1/2 for PF-06895751 When PF-06463922 Given Alone and With Rifampin29.14 ± 7.5418.43 ± 4.10
SecondaryPlasma Cmax for PF-06895751 When PF-06463922 Given Alone and With Rifampin

Cmax was the maximum observed plasma concentration. The PK parameter analysis population was defined as all participants enrolled and treated who have at least 1 of the PF-06463922 PK parameters of primary interest in at least 1 treatment period. PF-06895751 was the metabolite of PF-06463922.

Time frame:
Predose, 0.5, 1, 1.5, 2, 4, 6, 12, 24, 36, 48, 60, 72, 96, 120 hours postdose on Day 1 after PF-06463922 100 mg administration in Period 1, and at the same time points on Day 8 after PF-06463922 100 mg with rifampin administration in Period 2.
Reported as:
Geometric mean · ng/mL
Plasma Cmax for PF-06895751 When PF-06463922 Given Alone and With Rifampin
ng/mLPF-06463922 100 mgRifampin 600 mg + PF-06463922 100 mg
Plasma Cmax for PF-06895751 When PF-06463922 Given Alone and With Rifampin59.02 ± 2976.45 ± 38
SecondaryPlasma Molecular Weight Adjusted Metabolite to Parent (M/P) Ratio for Cmax (MRCmax) of PF-06463922 and Its Metabolite: When PF-06463922 Given Alone and With Rifampin

Cmax was the maximum observed plasma concentration of PF-06463922 and PF-06895751 ( metabolite of PF-06463922). The molecular weight adjusted metabolite/parent ratio (PF-06895751/PF-06463922) for Cmax was presented. The PK parameter analysis population was defined as all participants enrolled and treated who have at least 1 of the PF-06463922 PK parameters of primary interest in at least 1 treatment period.

Time frame:
Predose, 0.5, 1, 1.5, 2, 4, 6, 12, 24, 36, 48, 60, 72, 96, 120 hours postdose on Day 1 after PF-06463922 100 mg administration in Period 1, and at the same time points on Day 8 after PF-06463922 100 mg with rifampin administration in Period 2.
Reported as:
Geometric mean · ratio
Plasma Molecular Weight Adjusted Metabolite to Parent (M/P) Ratio for Cmax (MRCmax) of PF-06463922 and Its Metabolite: When PF-06463922 Given Alone and With Rifampin
ratioPF-06463922 100 mgRifampin 600 mg + PF-06463922 100 mg
Plasma Molecular Weight Adjusted Metabolite to Parent (M/P) Ratio for Cmax (MRCmax) of PF-06463922 and Its Metabolite: When PF-06463922 Given Alone and With Rifampin0.2094 ± 291.136 ± 35
SecondaryPlasma Molecular Weight Adjusted Metabolite to Parent (M/P) Ratio for AUClast (MRAUClast) of PF-06463922 and Its Metabolite: When PF-06463922 Given Alone and With Rifampin

AUClast was the plasma area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration of PF-06463922 and PF-06895751 ( metabolite of PF-06463922). The molecular weight adjusted metabolite/parent ratio (PF-06895751/PF-06463922) for AUClast was presented. The PK parameter analysis population was defined as all participants enrolled and treated who have at least 1 of the PF-06463922 PK parameters of primary interest in at least 1 treatment period. PF-06895751 was the metabolite of PF-06463922.

Time frame:
Predose, 0.5, 1, 1.5, 2, 4, 6, 12, 24, 36, 48, 60, 72, 96, 120 hours postdose on Day 1 after PF-06463922 100 mg administration in Period 1, and at the same time points on Day 8 after PF-06463922 100 mg with rifampin administration in Period 2.
Reported as:
Geometric mean · ratio
Plasma Molecular Weight Adjusted Metabolite to Parent (M/P) Ratio for AUClast (MRAUClast) of PF-06463922 and Its Metabolite: When PF-06463922 Given Alone and With Rifampin
ratioPF-06463922 100 mgRifampin 600 mg + PF-06463922 100 mg
Plasma Molecular Weight Adjusted Metabolite to Parent (M/P) Ratio for AUClast (MRAUClast) of PF-06463922 and Its Metabolite: When PF-06463922 Given Alone and With Rifampin1.053 ± 245.831 ± 56
SecondaryPlasma Molecular Weight Adjusted Metabolite to Parent (M/P) Ratio for AUCinf (MRAUCinf) of PF-06463922 and Its Metabolite: When PF-06463922 Given Alone and With Rifampin

AUCinf was the plasma area under the plasma concentration-time profile from time 0 extrapolated to infinite time of PF-06463922 and PF-06895751 ( metabolite of PF-06463922). The molecular weight adjusted metabolite/parent ratio (PF-06895751/PF-06463922) for AUCinf was presented. The PK parameter analysis population was defined as all participants enrolled and treated who have at least 1 of the PF-06463922 PK parameters of primary interest in at least 1 treatment period.

Time frame:
Predose, 0.5, 1, 1.5, 2, 4, 6, 12, 24, 36, 48, 60, 72, 96, 120 hours postdose on Day 1 after PF-06463922 100 mg administration in Period 1, and at the same time points on Day 8 after PF-06463922 100 mg with rifampin administration in Period 2.
Reported as:
Geometric mean · ratio
Plasma Molecular Weight Adjusted Metabolite to Parent (M/P) Ratio for AUCinf (MRAUCinf) of PF-06463922 and Its Metabolite: When PF-06463922 Given Alone and With Rifampin
ratioPF-06463922 100 mgRifampin 600 mg + PF-06463922 100 mg
Plasma Molecular Weight Adjusted Metabolite to Parent (M/P) Ratio for AUCinf (MRAUCinf) of PF-06463922 and Its Metabolite: When PF-06463922 Given Alone and With Rifampin1.166 ± 255.521 ± 56
Other pre-specifiedNumber of Participants With End of Study Abnormal Laboratory Findings Meeting the Criteria of Potentially Significant Clinical Concern

The total number of participants with laboratory test abnormalities was assessed. Clinical laboratory tests included hematology, chemistry, urinalysis and some other tests (including follicle-simulating hormone\[FSH\], urine drug screening, hepatitis B surface antigen \[HBsAg\], hepatitis B core antibody \[HBcAb\], hepatitis C virus antibody \[HCVAb\] and human immunodeficiency virus \[HIV\]. Clinical significance was judged by the investigator.

Time frame:
Baseline to about 18 days after the first PF-06463922 dose
Reported as:
Count of participants · Participants
Number of Participants With End of Study Abnormal Laboratory Findings Meeting the Criteria of Potentially Significant Clinical Concern
ParticipantsPF-06463922 100 mgRifampin 600 mg QDRifampin 600 mg + PF-06463922 100 mg
No. of Participants Evaluable for Lab. Abnormality121212
No. With Lab. Abnormalities5611
Other pre-specifiedNumber of Participants With Physical Examination Findings Meeting the Criteria of Potentially Significant Clinical Concern

A full physical examination included head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, gastrointestinal, musculoskeletal, and neurological systems. The limited or abbreviated physical examination focused on general appearance, the respiratory and cardiovascular systems, as well as towards participant reported symptoms. Clinical significance was judged by the investigator.

Time frame:
Baseline to about 18 days after the first PF-06463922 dose.
Reported as:
Count of participants · Participants
Number of Participants With Physical Examination Findings Meeting the Criteria of Potentially Significant Clinical Concern
ParticipantsPF-06463922 100 mgRifampin 600 mg + PF-06463922 100 mg
Number of Participants With Physical Examination Findings Meeting the Criteria of Potentially Significant Clinical Concern00
Other pre-specifiedNumber of Participants With Changes From Baseline and Absolute Values in Vital Signs Meeting the Criteria of Potentially Significant Clinical Concerns

Criteria for potentially clinically important changes in vital signs were defined as: supine and standing systolic blood pressure (SBP) of less than (\<90) millimeters of mercury (mm Hg) or change in supine and standing SBP more than or equal to (\>=) 30 mm Hg; supine and standing diastolic blood pressure (DBP) of \< 50 mm Hg or change in supine and standing DBP of \>= 20 mm Hg; supine and standing pulse rate of \< 40 or \>120 beats per minute (bpm). Figure "99999" signifies data not measurable/applicable. Maximum Decrease is abbreviated as Max.Dec., and Maximum Increase is abbreviated as Max.Inc. n is the number of participants contributing to the parameter, not applicable is abbreviated as N/A.

Time frame:
Baseline to about 18 days after the first PF-06463922 dose.
Reported as:
Count of participants · Participants
Number of Participants With Changes From Baseline and Absolute Values in Vital Signs Meeting the Criteria of Potentially Significant Clinical Concerns
ParticipantsPF-06463922 100 mgRifampin 600 mg + PF-06463922 100 mg
Supine SBP (mmHg) <9001
Standing SBP (mmHg) <90—0
Supine DBP (mmHg) <5000
Standing DBP (mmHg) <50—0
Supine PR (BPM) >12000
Supine PR (BPM) <4000
Standing PR (BPM) >120—0
Standing PR (BPM) <40—0
Max.Dec. From Baseline in Supine SBP (mm Hg) >=3000
Max.Dec. From Baseline in Supine DBP (mm Hg) >=2000
Max.Inc. From Baseline in Supine SBP (mm Hg) >=3001
Max.Inc. From Baseline in Supine DBP (mm Hg) >=2000
Other pre-specifiedNumber of Participants With Electrocardiogram (ECG) Findings Meeting the Criteria of Potentially Significant Clinical Concerns

PR interval was the interval between the start of the P wave and the start of the QRS complex, corresponding to the time between the onset of the atrial depolarization and onset of ventricular depolarization. Criteria for potentially clinically important changes (chg) in ECG were defined as: absolute values of PR interval \>=200 to \<220 msec, \>=220 to \<240 msec, \>=240 to \<260 msec and \>=260 msec. Increase from baseline \>=40, \<60, \>=60 and \<80, \>=80, and relative change from baseline \>25%. The beginning of the Q wave to the end of the T wave corresponding to electrical systole (QT) interval corrected using the Fridericia formular (QTCF) of 450 to \<480 msec, 480 to \<500 msec and \>=500 msec, or an increase of 30 to \<60 msec of \>=60 msec. Maximum is abbreviated as Max.

Time frame:
Baseline to about 18 days after the first PF-06463922 dose.
Reported as:
Count of participants · Participants
Number of Participants With Electrocardiogram (ECG) Findings Meeting the Criteria of Potentially Significant Clinical Concerns
ParticipantsPF-06463922 100 mgRifampin 600 mg + PF-06463922 100 mg
Maximum (Max) PR Interval (msec) 200-<22000
Max PR Interval (msec) 220-<24000
Max PR Interval (msec) 240-<26000
Max PR Interval (msec) >=26000
Max QT Interval (msec) >=50001
Max QTCF Interval (msec) 450-<48001
Max QTCF Interval (msec) 480-<50000
Max QTCF Interval (msec) >=50000
Max PR Interval Inc. From Baseline (msec) 40-<6000
Max PR Interval Inc. From Baseline (msec) 60-<8000
Max PR Interval Inc. From Baseline (msec) >=8000
Max PR Interval Inc.From Baseline(msec)PctChg>25%00
Max QTCF Inc. From Baseline (msec) 30<=Chg<6001
Max QTCF Inc. From Baseline (msec) Chg>=6000
Other pre-specifiedNumber of Participants With Concomitant Treatments Meeting the Criteria of Potentially Significant Clinical Concerns

Participants abstained from all concomitant treatments, except for the treatment of adverse events. Limited use of non-prescription medications that were not believed to affect participant safety or the overall results of the study might be permitted on a case by case basis following approval by the sponsor. All participants were questioned about concomitant treatment at each clinic visit. Treatments taken within 28 days before the first dose of study investigational product were documented as a prior treatment. Treatment taken after the first dose of study investigational product were documented as concomitant treatments. Females taking hormone replacement therapy might be eligible to participate in this study if they were willing to discontinue therapy at least 28 days prior to the first dose of study treatment and remained off hormonal therapy for duration of the study. Clinical significance was judged by the investigator.

Time frame:
Baseline to about 18 days after the first PF-06463922 dose.
Reported as:
Count of participants · Participants
Number of Participants With Concomitant Treatments Meeting the Criteria of Potentially Significant Clinical Concerns
ParticipantsPF-06463922 100 mgRifampin 600 mg + PF-06463922 100 mg
Number of Participants With Concomitant Treatments Meeting the Criteria of Potentially Significant Clinical Concerns00
Other pre-specifiedNumber of Participants With Treatment-Emergent Adverse Events (TEAEs) (All Causalities and Treatment-Related)

An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event need not necessarily have a casual relationship with the treatment or usage. A serious adverse event (SAE) was any untoward medical occurrence at any dose that: 1) resulted in death; 2) was life threatening (immediate risk of death); 3) required inpatient hospitalization or prolongation of existing hospitalization; 4) resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); 5) resulted in congenital anomaly/birth defect. TEAE included both non-serious adverse events and serious adverse events.

Time frame:
Baseline to about 18 days after the first PF-06463922 dose.
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) (All Causalities and Treatment-Related)
ParticipantsPF-06463922 100 mgRifampin 600 mg QDRifampin 600 mg + PF-06463922 100 mg
No. of Participants with AEs (all Causalities)1512
No. of Participants with SAEs (all Causalities)005
Participants with Severe AEs (all Causalities)007
Discontinued due to AEs (all Causality)0012
No. of Participants with AEs (Treatment Related)1412
No. of Participants with SAEs (Treatment Related)005
Participants with Severe AEs (Treatment Related)007
Discontinued due to AEs (Treatment Related)0012

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PF-06463922 100 mg—0/12 (0%)1/12 (8.3%)
Rifampin 600 mg QD—0/12 (0%)5/12 (41.7%)
Rifampin 600 mg + PF-06463922 100 mg—5/12 (41.7%)11/12 (91.7%)
Most frequent serious events
Most frequent serious events
EventPF-06463922 100 mgRifampin 600 mg QDRifampin 600 mg + PF-06463922 100 mg
Drug-induced liver injuryHepatobiliary disorders0/120/125/12
Most frequent other events
Showing 10 of 21
Most frequent other events
EventPF-06463922 100 mgRifampin 600 mg QDRifampin 600 mg + PF-06463922 100 mg
NauseaGastrointestinal disorders0/120/129/12
Drug-induced liver injuryHepatobiliary disorders0/120/127/12
VomitingGastrointestinal disorders0/120/123/12
DizzinessNervous system disorders1/120/123/12
DyspepsiaGastrointestinal disorders0/120/122/12
Decreased appetiteMetabolism and nutrition disorders0/120/122/12
Dry eyeEye disorders0/121/121/12
PhotophobiaEye disorders0/121/121/12
Abdominal painGastrointestinal disorders0/120/121/12
Abdominal pain lowerGastrointestinal disorders0/120/121/12

Baseline characteristics

Age, Continuous
Age, Continuous(years)Entire Study
Mean36.5 ± 11.1
Sex: Female, Male
Sex: Female, Male(Participants)Entire Study
Female1
Male11
08

Study locations

1 site
  • Pfizer New Haven Clinical Research Unit
    New Haven, Connecticut 06511, United States
09

References and documents

Publications

  • Chen J, Xu H, Pawlak S, James LP, Peltz G, Lee K, Ginman K, Bergeron M, Pithavala YK. The Effect of Rifampin on the Pharmacokinetics and Safety of Lorlatinib: Results of a Phase One, Open-Label, Crossover Study in Healthy Participants. Adv Ther. 2020 Feb;37(2):745-758. doi: 10.1007/s12325-019-01198-9. Epub 2019 Dec 20. Erratum In: Adv Ther. 2020 Nov;37(11):4754. doi: 10.1007/s12325-020-01480-1. PubMed 31863284 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2016 to primary completion in Oct 2016, 3 months.

Results were first posted in Jan 2019, 2 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2016
First posted
Jun 17, 2016
StartActual
Jul 2016
Primary completionActual
Oct 2016
CompletionActual
Oct 2016
Results first posted
Jan 25, 2019
Last update
Jan 25, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 25, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02804399
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jun 17, 2016
Start date
Jul 2016
Primary completion
Oct 2016
Completion
Oct 2016
Results posted
Jan 25, 2019
Last update
Jan 25, 2019

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lorlatinib

Start the discussion